Cargando…

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα

Obesity triggers the development of non-alcoholic fatty liver disease (NAFLD), which involves alterations of regulatory transcription networks and epigenomes in hepatocytes. Here we demonstrate that G protein pathway suppressor 2 (GPS2), a subunit of the nuclear receptor corepressor (NCOR) and histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Ning, Damdimopoulos, Anastasius, Goñi, Saioa, Huang, Zhiqiang, Vedin, Lise-Lotte, Jakobsson, Tomas, Giudici, Marco, Ahmed, Osman, Pedrelli, Matteo, Barilla, Serena, Alzaid, Fawaz, Mendoza, Arturo, Schröder, Tarja, Kuiper, Raoul, Parini, Paolo, Hollenberg, Anthony, Lefebvre, Philippe, Francque, Sven, Van Gaal, Luc, Staels, Bart, Venteclef, Nicolas, Treuter, Eckardt, Fan, Rongrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459876/
https://www.ncbi.nlm.nih.gov/pubmed/30975991
http://dx.doi.org/10.1038/s41467-019-09524-z
Descripción
Sumario:Obesity triggers the development of non-alcoholic fatty liver disease (NAFLD), which involves alterations of regulatory transcription networks and epigenomes in hepatocytes. Here we demonstrate that G protein pathway suppressor 2 (GPS2), a subunit of the nuclear receptor corepressor (NCOR) and histone deacetylase 3 (HDAC3) complex, has a central role in these alterations and accelerates the progression of NAFLD towards non-alcoholic steatohepatitis (NASH). Hepatocyte-specific Gps2 knockout in mice alleviates the development of diet-induced steatosis and fibrosis and causes activation of lipid catabolic genes. Integrative cistrome, epigenome and transcriptome analysis identifies the lipid-sensing peroxisome proliferator-activated receptor α (PPARα, NR1C1) as a direct GPS2 target. Liver gene expression data from human patients reveal that Gps2 expression positively correlates with a NASH/fibrosis gene signature. Collectively, our data suggest that the GPS2-PPARα partnership in hepatocytes coordinates the progression of NAFLD in mice and in humans and thus might be of therapeutic interest.